2 unchanged sentences
Our common stock is listed for quotation on the Nasdaq Global Market under the trading symbol “TVTX” and is part of the Nasdaq Biotechnology Index (Nasdaq:
−Removed: Prior to our name change in November 2020, we traded under the symbol "RTRX."
As of February 22, 2022, the last reported sale price of our Common Stock as reported by the Nasdaq was $27.94.
11 unchanged sentences
Payment of dividends in the future will depend upon our earnings, capital requirements and other factors which our Board of Directors may deem relevant.
−Removed: SELECTED FINANCIAL DATA
−Removed: The following table presents selected historical financial data of the Company for the periods indicated.
−Removed: The selected historical financial information is derived from the audited Consolidated Financial Statements of the Company referred to under Item 8 of this Annual Report on Form 10-K, and previously published historical financial statements.
−Removed: The following selected financial data should be read in conjunction with Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations, and the Company’s Consolidated Financial Statements, including the notes thereto, included elsewhere herein.
−Removed: Selected historical financial data ( in thousands, except share and per share amounts ):
−Removed: For the year ended December 31,
−Removed: Consolidated Statement of Operations:
−Removed: 2020 2019 2018 2017 2016
−Removed: Net product sales $ 198,321 $ 175,338 $ 164,246 $ 154,937 $ 133,591
−Removed: Total operating expenses 374,484 312,699 244,286 208,728 191,805
−Removed: Operating loss (176,163) (137,361) (80,040) (53,791) (58,214)
−Removed: Total other income (expenses), net (12,627) (9,087) (21,827) (4,572) 632
−Removed: Income (Loss) before benefit (provision) for income taxes (188,790) (146,448) (101,867) (58,363) (57,582)
−Removed: Income tax benefit (provision) 19,359 21 (811) (1,368) 9,679
−Removed: Net income (loss) $ (169,431) $ (146,427) $ (102,678) $ (59,731) $ (47,903)
−Removed: Per Share Data:
−Removed: Net Income (loss) per common share, basic $ (3.56) $ (3.46) $ (2.54) $ (1.54) $ (1.29)
−Removed: Net Income (loss) per common share, diluted $ (3.56) $ (3.46) $ (2.54) $ (1.54) $ (1.29)
−Removed: Weighted average common shares outstanding, basic 47,539,631 42,339,961 40,433,171 38,769,816 36,997,865
−Removed: Weighted average common shares outstanding, diluted 47,539,631 42,339,961 40,433,171 38,769,816 38,288,012
−Removed: As of December 31,
−Removed: Balance Sheet data:
−Removed: 2020 2019 2018 2017 2016
−Removed: Cash, cash equivalents and marketable securities $ 361,589 $ 398,524 $ 471,541 $ 300,630 $ 255,873
−Removed: Working capital 317,747 333,615 391,057 240,139 249,090
−Removed: Total assets 607,439 604,800 709,160 520,346 525,282
−Removed: Long-term debt 215,339 204,861 195,091 45,077 44,422
−Removed: Total stockholders’ equity $ 211,213 $ 221,196 $ 318,253 $ 293,134 $ 307,767
−Removed: Cash dividends were not paid during the above periods.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.